
Sign up to save your podcasts
Or
Join me as I sit down with Dr. Hamid Khoja, Ph.D. His newest research is looking at using fibroblast cell therapy to help slow the progression of MS as well as potentially remyelinate and recover previously lost function. This research is still in the very early phases of development, but the results have been promising and exciting, so I wanted to have Dr. Khoja share his research with you!
Dr. Hamid Khoja, is Chief Scientific Officer for FibroBiologics, a biopharmaceutical and regenerative medicine company, where he leads all research, development, and advancement for the pipeline of fibroblast cell therapy candidates. Hamid has more than 25 years of experience as a leader of scientific teams, in the development of cell-based genomic, proteomic, and epigenetics assays, and of tools, protocols, and technologies for use in drug discovery and development as well as clinical diagnostics.
Hamid has served as the Principal Scientist at Covaris, where he led the effort in successfully incorporating their technology into Illumina Next Generation Sequencing protocols, managed external collaborations for product and applications development, and assessed new technologies for acquisition.
Links:
https://www.linkedin.com/company/fibrobiologics/
https://twitter.com/FibroBiologics
https://www.facebook.com/FibroBiologics
Additional Resources: https://www.doctorgretchenhawley.com/insider
Reach out to Me: [email protected]
Website: www.MSingLink.com
Social:
★ Facebook: https://www.facebook.com/groups/mswellness
★ Instagram: https://www.instagram.com/doctor.gretchen
★ YouTube: https://www.youtube.com/c/doctorgretchenhawley?sub_confirmation=1
→ Game Changers Course: https://www.doctorgretchenhawley.com/GameChangersCourse
→ Total Core Program: https://www.doctorgretchenhawley.com/TotalCoreProgram
→ The MSing Link: https://www.doctorgretchenhawley.com/TheMSingLink
4.9
105105 ratings
Join me as I sit down with Dr. Hamid Khoja, Ph.D. His newest research is looking at using fibroblast cell therapy to help slow the progression of MS as well as potentially remyelinate and recover previously lost function. This research is still in the very early phases of development, but the results have been promising and exciting, so I wanted to have Dr. Khoja share his research with you!
Dr. Hamid Khoja, is Chief Scientific Officer for FibroBiologics, a biopharmaceutical and regenerative medicine company, where he leads all research, development, and advancement for the pipeline of fibroblast cell therapy candidates. Hamid has more than 25 years of experience as a leader of scientific teams, in the development of cell-based genomic, proteomic, and epigenetics assays, and of tools, protocols, and technologies for use in drug discovery and development as well as clinical diagnostics.
Hamid has served as the Principal Scientist at Covaris, where he led the effort in successfully incorporating their technology into Illumina Next Generation Sequencing protocols, managed external collaborations for product and applications development, and assessed new technologies for acquisition.
Links:
https://www.linkedin.com/company/fibrobiologics/
https://twitter.com/FibroBiologics
https://www.facebook.com/FibroBiologics
Additional Resources: https://www.doctorgretchenhawley.com/insider
Reach out to Me: [email protected]
Website: www.MSingLink.com
Social:
★ Facebook: https://www.facebook.com/groups/mswellness
★ Instagram: https://www.instagram.com/doctor.gretchen
★ YouTube: https://www.youtube.com/c/doctorgretchenhawley?sub_confirmation=1
→ Game Changers Course: https://www.doctorgretchenhawley.com/GameChangersCourse
→ Total Core Program: https://www.doctorgretchenhawley.com/TotalCoreProgram
→ The MSing Link: https://www.doctorgretchenhawley.com/TheMSingLink
12,915 Listeners
2,023 Listeners
4,931 Listeners
1,958 Listeners
142 Listeners
93 Listeners
47 Listeners
116 Listeners
1,239 Listeners
3,323 Listeners
12,348 Listeners
41,435 Listeners
36 Listeners
20,604 Listeners
3,526 Listeners